Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

697
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
697
T Cell Types and Functions01:24

T Cell Types and Functions

996
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
996

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same author

Clinicogenomic analysis of <i>EGFR</i>-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.

Science translational medicine·2026
Same author

Hierarchical classification of immune cell transcriptomes at population-scale.

bioRxiv : the preprint server for biology·2026
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026
Same author

Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers.

Blood cancer discovery·2026
Same author

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction.

bioRxiv : the preprint server for biology·2026
Same journal

Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment.

Cancer immunology research·2026
Same journal

Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion.

Cancer immunology research·2026
Same journal

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Cancer immunology research·2026
Same journal

Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy.

Cancer immunology research·2026
Same journal

ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy.

Cancer immunology research·2026
Same journal

DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies.

Cancer immunology research·2026
查看所有相关文章

相关实验视频

Updated: Jun 22, 2025

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.4K

使用LIGHT增强CAR T细胞功能

Winson Cai1,2, Kento Tanaka3, Xiaoli Mi3

  • 1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer immunology research
|July 3, 2024
PubMed
概括
此摘要是机器生成的。

化学抗原受体 (CAR) T细胞疗法在固体瘤中表现有前途,通过设计CAR T细胞来表达LIGHT. 这增强了瘤细胞的杀死,并可能防止抗原阴性疾病的复发.

更多相关视频

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

相关实验视频

Last Updated: Jun 22, 2025

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.4K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞治疗对B细胞癌症有效,但由于向抗原异质性,在固体瘤中面临挑战.
  • 在固体瘤治疗中,抗原逃逸和复发仍然是CAR T细胞治疗的重大障碍.

研究的目的:

  • 开发一种新的CAR T细胞策略,以克服固体瘤中的抗原异质性.
  • 通过结合LIGHT介导,抗原独立的瘤细胞杀死来增强CAR T细胞的疗效.

主要方法:

  • 工程CAR T细胞过度表达LIGHT,一种与癌细胞上的淋巴毒素-β受体 (LTBR) 和免疫细胞上的疹病毒进入介质 (HVEM) 相互作用的配体.
  • 评估了工程CAR T细胞的双机制细胞毒性 (CAR介导和LIGHT介导) 和免疫刺激性质.

主要成果:

  • 光表达的CAR-T细胞表现出CAR-依赖的,抗原特异性杀死以及对瘤细胞的光依赖的,抗原独立的细胞毒性.
  • 在经过工程改造以表达LIGHT的CAR T细胞中观察到增强的增殖和改善的细胞解剖特征.
  • 双重作用的CAR T细胞显示出消除抗原阴性瘤细胞的潜力,解决了复发的关键原因.

结论:

  • 光表达的CAR T细胞提供了一种有前途的策略,以克服固体瘤中的抗原异质性.
  • 这种方法提高了CAR T细胞的持续性和有效性,可能防止疾病复发.
  • 轻工设计的CAR T细胞代表了固体瘤免疫疗法的潜在进步.